| Code | CSB-RA011649MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to daclizumab, targeting IL2RA (interleukin-2 receptor alpha chain, also known as CD25). IL2RA is a critical component of the high-affinity IL-2 receptor complex, expressed primarily on activated T cells, regulatory T cells, and certain immune cell subsets. By binding to IL2RA, this antibody blocks IL-2 signaling, a pathway essential for T cell proliferation, differentiation, and immune response regulation. Dysregulation of IL2RA expression is implicated in various conditions including autoimmune diseases, transplant rejection, and hematological malignancies, making it a valuable therapeutic target for immune modulation.
Daclizumab, the reference antibody, is a humanized IgG1 monoclonal antibody originally developed for preventing acute organ rejection in transplant recipients. This biosimilar provides researchers with a cost-effective tool for investigating IL-2/IL2RA-mediated immune mechanisms, studying T cell biology, exploring immunosuppressive strategies, and evaluating therapeutic approaches for autoimmune disorders and transplantation research. It serves as an important reagent for immunological studies requiring specific IL2RA blockade.
There are currently no reviews for this product.